Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

Trial Profile

Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Niraparib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-162; TOPACIO
  • Sponsors TESARO
  • Most Recent Events

    • 05 Jun 2018 Results (n=62, data cut off: Jan 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (data cut off Jan 2018; n=54) evaluating the safety and efficacy of combination treatment with niraparib + pembrolizumab in patients with metastatic triple-negative breast cancer, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2018 According to a TESARO media release, data from this study presented at at 2018 ASCO Annual Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top